AstraZeneca Mexico – Ugo de Jacobis, President
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives. The company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). It is also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. In Mexico the company relies on manufacturing capabilities and a staff of 150 people.
Contact details
AstraZeneca S.A. de C.V.
Periférico Sur No. 4305, 5to piso
Col. Jardines de la Montaña, Del. Tlalpan
CP 14210 México DF
MEXICO
Tel: +52 (55) 5374 9600
Website: www.astrazeneca.com/mexico
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place.…
Eduardo Tapia explains how big changes in the distribution landscape are transforming the industry, reveals how the life sciences sector has been positioned as a global priority for DHL, and…
Eric Alvarez, managing director of Janssen Mexico, explains why it is important to distinguish between the public and private sector when discussing the latest developments in the pharmaceutical industry, and…
Teleflex is committed to solving the challenges of a changing healthcare environment in the areas of critical care and surgical applications by providing every day new products. The managing director…
Internationalization and innovation are part of Chiesi’s history. The general manager of the recently started Mexican affiliate discusses the company’s priorities for the second largest market in Latin America and…
Cecilia Calderón shares her experience as founder and general manager of Vigpharma, her perspectives on the pharmacovigilance and technovigilance in Mexico and the main challenges that come with being the…
The director of Bacher Zoppi reveals how the Mexican pharma sector is back in the spotlight of the international investor community, explains how the distribution environment has evolved with power…
The corporate development director and business development manager of UpPharma explain why Market Expansion Services (MES) model represents a unique business opportunity for firms looking to establish themselves in the…
The councillor at the Swiss Embassy talks about how the two countries have a particularly close relationship when it comes to pharma, the challenge of introducing innovative products to the…
José Angel García Hinojosa, vice president sales and marketing of the Grupo Loeffler Russek, discusses the history of the company since its establishment until its most recent accomplishments. Always with…
Landsteiner is betting on biotech and genomics. The head of new developments and the head of genomic research share their views on the future of the company as well as…
The president and founder of Knobloch Information Group, the leading supplier of market data to the pharmaceutical industry in Mexico, provides an in-depth overlook about the most important changes that…
Innovation is a product’s added value, ensuring that the patient is ready to buy. The former director of R&D and today CEO of Carnot explains how the company is undergoing…
See our Cookie Privacy Policy Here